Noacid (Pantoprazole Sodium Sesquihydrate)

Pantoprazole is a proton pump inhibitor that reduces gastric acid production, making it useful for several acid‑related gastrointestinal conditions.

• Erosive esophagitis: promotes healing of inflamed esophageal lining by lowering acid exposure.
• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and prevents reflux‑related damage.
• Acute gastric ulcer bleeding: stabilises clot formation and reduces re‑bleeding risk by suppressing acid.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion caused by gastrin‑producing tumors.

• Pantoprazole sodium sesquihydrate is converted to its active sulfonamide form, which binds irreversibly to the cysteine residues of the H⁺/K⁺‑ATPase (proton pump) located on gastric parietal cell membranes. This covalent inhibition blocks the final step of acid secretion, leading to a sustained reduction in gastric acidity for up to 24 hours after a single intravenous dose.

Pantoprazole administered intravenously may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild pain or pressure sensation in the head.
• Diarrhea: loose, watery stools occurring during treatment.
• Nausea: feeling of sickness or urge to vomit.
• Abdominal pain: discomfort or cramping in the stomach area.
• Rash: skin redness or mild eruption.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with breathing difficulty and hypotension.
• Clostridioides difficile infection: severe colitis presenting with profuse diarrhea.
• Thrombocytopenia: marked reduction in platelet count leading to bleeding risk.
• Elevated liver enzymes: significant increase in ALT/AST indicating hepatic stress.
• Stevens‑Johnson syndrome: rare severe skin and mucous membrane disorder.

When using Noacid, clinicians should observe several precautionary measures to ensure patient safety and product integrity.

• Assess renal function: adjust or monitor dosing in patients with impaired kidney clearance.
• Monitor liver enzymes: periodic testing is advised as hepatic metabolism may be affected.
• Use cautiously in the elderly: increased susceptibility to electrolyte disturbances and infections.
• Review concomitant medications: avoid or closely watch drugs that require gastric acidity for absorption.
• Discontinue if allergic reaction occurs: stop infusion immediately and provide appropriate emergency care.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole can affect the pharmacokinetics of several medicines; awareness of key interactions helps prevent therapeutic failures or toxicity.

Major Interactions (Avoid)

• Ketoconazole, itraconazole, posaconazole: reduced antifungal absorption due to increased gastric pH.
• Atazanavir and other protease inhibitors: markedly decreased plasma concentrations.
• Clopidogrel: diminished activation leading to reduced antiplatelet effect.
• Warfarin: potential increase in INR and bleeding risk.
• Methotrexate (high dose): impaired renal clearance may raise toxicity.

Moderate Interactions (Monitor Closely)

• Digoxin: modest increase in serum levels; monitor for toxicity.
• HIV protease inhibitors (e.g., ritonavir): may require dose adjustment.
• Oral contraceptives: possible reduction in efficacy; advise backup method.
• Diazepam: slight increase in sedation; observe patient response.
• Calcium carbonate supplements: may interfere with absorption; separate dosing times.